Le Lézard
Classified in: Health
Subject: PER

HOPA Board President Begins Term by Sharing Gratitude and Goals


MILWAUKEE, April 18, 2021 /PRNewswire-PRWeb/ -- The Hematology/Oncology Pharmacy Association (HOPA) board leaders for 2021-2022 began their terms today during HOPA's virtual annual conference. Larry W. Buie, PharmD, BCOP, FASHP, Clinical Pharmacy Manager at Memorial Sloan Kettering Cancer Center will serve as Board President while Amber P. Lawson, PharmD, BCOP, Program Coordinator at University of Kentucky HealthCare and Andrea Iannucci, PharmD, BCOP, Assistant Chief Pharmacist at University of California Davis Medical Center will serve as Secretary and Member-At-Large, respectively.

As Board President, Dr. Buie hopes to expand HOPA's reach by making inroads with pharmacy students, prioritizing patient advocacy, and focusing on diversity, equity and inclusion within the pharmacy profession and HOPA. His board presidency begins mid-way through HOPA's 2020-2023 Strategic Plan.

In his inaugural address, Dr. Buie highlighted three particularly exciting new committees: an Oral Chemotherapy Collective; a Task Force for Student Engagement; and a Diversity, Equity and Inclusion Task Force. Also mentioned in his address were the many other HOPA committees, all of which are currently recruiting member volunteers.

In his incoming president's address, Dr. Buie, who is also PGY2 Adult Oncology Residency Program Director at Memorial Sloan Kettering, said working with residents has played a role in his career success and satisfaction. Among other attributes, he cited residents' commitment to health equity as a source of inspiration. Dr. Buie also paid tribute to his mentors, including those he met at the University of North Carolina Eshelman School of Pharmacy.

His address, entitled A Journey of Gratitude, was in memory of an educator and caregiver who was instrumental during Dr. Buie's teenage years.

About Dr. Larry W. Buie
Larry W. Buie, PharmD, BCOP, FASHP is a Clinical Pharmacy Manager and PGY2 Adult Oncology Residency Program Director at Memorial Sloan Kettering Cancer Center, in New York, NY, where he had previously worked in direct patient care. He has been a Board Certified Oncology Pharmacist since 2008 and is a Fellow of the American Society of Health-Systems Pharmacists. Dr. Buie received his Doctor of Pharmacy degree from the University of North Carolina Eshelman School of Pharmacy in Chapel Hill, NC in 2005. Dr. Buie has made multiple contributions to medical literature and routinely provides continuing education to pharmacists in a variety of settings. He has been a HOPA member since 2008.

About HOPA
The Hematology/Oncology Pharmacy Association (HOPA) supports hematology/oncology pharmacy professionals and promotes the role of the pharmacist in collaborative cancer care. Founded in 2004, HOPA provides crucial education, networking, and advancement opportunities frequently sought by pharmacists, pharmacy interns, residents, fellows, students, technicians, researchers, and administrators who specialize in hematology/oncology pharmacy. Its vision is to ensure that all individuals affected by cancer have a hematology/oncology pharmacist as an integral member of their care team.

###

Media Contact

Michelle Sieg, HOPA, 4142318104, [email protected]

Twitter

 

SOURCE Hematology/Oncology Pharmacy Association


These press releases may also interest you

at 02:48
Today, RaySearch Laboratories AB (publ)  publishes its Annual Report for the financial year 2023. The report is held available on RaySearch's website, under the section Investors.  This information is information that RaySearch Larboratiories AB...

at 02:43
Shareholders of Zinzino AB (publ) are hereby invited to the annual general meeting on Monday, May 27, 2024, at 1:30 PM at the company's premises at Hulda Mellgrens gata 5 in Gothenburg. Registration begins at 1:15 PM. The company aims to webcast the...

at 02:41
Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2023. The annual report is now available on the company's website. "Implantica had a very...

at 02:08
Revenue amounted to ?498.8m (?419.3m), an increase of 18.9% with an organic growth of 14.2%.Operating profit (EBIT) was ?19.0m (?10.7m), an increase of 78.0%, representing an operating margin of 3.8% (2.6%).Net profit amounted to ?6.5m (?2.1m), which...

at 02:00
Amwins Global Risks is delighted to announce Classic Cars and Cotswolds, an auction to raise money for the Matthew Wilson Multiple Myeloma Fund at Blood Cancer UK. The online auction opens today and features Ferraris, Aston Martins, a Rolls Royce, a...

at 01:35
Regulatory News: Sensorion (FR0012596468 ? ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces...



News published on and distributed by: